The Food and Drug Administration yesterday approved using the antiviral treatment Xofluza (baloxavir marboxil) to prevent flu in patients age 12 or older who have been exposed to someone with flu.

“This expanded indication for Xofluza will provide an important option to help prevent influenza just in time for a flu season that is anticipated to be unlike any other because it will coincide with the coronavirus pandemic,” said Debra Birnkrant, M.D., director of the FDA’s Division of Antiviral Products.

Related News Articles

Headline
The National Academy of Medicine has named an international committee to assess how COVID-19 vaccine development and other policies could facilitate global…
Headline
To continue emphasizing the message of protecting against both the flu and COVID-19, AHA’s Wear A Mask and United Against the Flu campaigns today released new…
Headline
This podcast, in support of AHA’s national strategic alliance with the National Urban League, is bringing attention to health inequities in Black and…
Headline
The Food and Drug Administration Friday authorized the first prescription diagnostic test for both COVID-19 and influenza A and B that allows patients to…
Headline
Adam Myers, M.D., population health chief at Cleveland Clinic, talks with Nancy Foster, AHA vice president for quality and patient safety, about preventing flu…
Headline
The Food and Drug Administration yesterday released an updated template for developers requesting emergency use authorization for antigen tests for…